
Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million, resulting in a 8.21% decrease from last quarter. In Q4, Kymera Therapeutics brought in $15.28 million in sales but lost $33.90 million in earnings.